Top risk of stroke for normal-weight adults: Getting under 6 hours of sleep

 

Stroke risk greatest for employed middle to older ages, normal weight and no sleep apnea, habitually sleeping less than 6 hours each day

 

Darien, IL, USA (June 11, 2012) – Habitually sleeping less than six hours a night significantly increases the risk of stroke symptoms among middle-age to older adults who are of normal weight and at low risk for obstructive sleep apnea (OSA), according to a study of 5,666 people followed for up to three years.

 

The participants had no history of stroke, transient ischemic attack, stroke symptoms or high risk for OSA at the start of the study, being presented today at SLEEP 2012. Researchers from the University of Alabama at Birmingham recorded the first stroke symptoms, along with demographic information, stroke risk factors, depression symptoms and various health behaviors.

 

After adjusting for body-mass index (BMI), they found a strong association with daily sleep periods of less than six hours and a greater incidence of stroke symptoms for middle-age to older adults, even beyond other risk factors. The study found no association between short sleep periods and stroke symptoms among overweight and obese participants.

 

"In employed middle-aged to older adults, relatively free of major risk factors for stroke such as obesity and sleep-disordered breathing, short sleep duration may exact its own negative influence on stroke development," said lead author Megan Ruiter, PhD. "We speculate that short sleep duration is a precursor to other traditional stroke risk factors, and once these traditional stroke risk factors are present, then perhaps they become stronger risk factors than sleep duration alone."

 

Further research may support the results, providing a strong argument for increasing physician and public awareness of the impact of sleep as a risk factor for stroke symptoms, especially among persons who appear to have few or no traditional risk factors for stroke, she said.

 

"Sleep and sleep-related behaviors are highly modifiable with cognitive-behavioral therapy approaches and/or pharmaceutical interventions," Ruiter said. "These results may serve as a preliminary basis for using sleep treatments to prevent the development of stroke."

 

Ruiter and colleagues collected their data as part of the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, led by George Howard, PhD, of the University of Alabama at Birmingham School of Public Health. REGARDS enrolled 30,239 people ages 45 and older between January 2003 and October 2007, and is continuing to follow them for health changes. The study is funded by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke.

 

 

The abstract "Short sleep predicts stroke symptoms in persons of normal weight" is being presented today at SLEEP 2012, the 26th annual meeting of the Associated Professional Sleep Societies (APSS) in Boston. To be placed on the mailing list for SLEEP 2012 press releases or to register for SLEEP 2012 press credentials, contact AASM PR Coordinator Doug Dusik at 630-737-9700 ext. 9364, or at ddusik@aasmnet.org

 

A joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, the annual SLEEP meeting brings together an international body of more than 5,500 leading clinicians and scientists in the fields of sleep medicine and sleep research. At SLEEP 2012, more than 1,300 research abstract presentations will showcase new findings that contribute to the understanding of sleep and the effective diagnosis and treatment of sleep disorders such as insomnia, narcolepsy and sleep apnea.

Follow @aasmorg on Twitter for live updates and use the official hashtag #SLEEP2012 to see what attendees are saying. "Like" the American Academy of Sleep Medicine on Facebook at Facebook.com/sleepmedicine for photos, videos and more.

 


 

American Academy of Sleep Medicine, 11.06.2012 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…